Akeila Bio

Akeila Bio is a biotechnology company focused on developing novel therapies for retinal diseases, with a primary emphasis on geographic atrophy (GA) and age-related macular degeneration (AMD). The company's approach centers on inhibiting the NLRP3 inflammasome, a key driver of neurodegeneration and cell death in the eye. By targeting the underlying inflammatory pathways triggered by Alu RNA accumulation, Akeila Bio aims to provide disease-modifying treatments that preserve vision. The company was founded based on pioneering research from the University of Virginia and is led by a team with deep expertise in ophthalmology and drug development.